Sprint Nextel ( S) rated new Buy at Kaufman Bros. $6.25 price target. Valuation call, as business is beginning to stabilize. Tellabs ( TLAB) rated new Market Perform at Wells Fargo. Legacy businesses still account for about half of sales. URS ( URS) rated new Buy at BB&T Capital. $59 price target. Company is among the leaders in multiple end markets.
At a time when healthcare investors seem especially primed for big, transformative biotech M&A, a deal in which Celgene acquires Biogen would be smart, profitable, opportunistic and certainly attention grabbing.